Match!
Gabriella Campadelli-Fiume
University of Bologna
Molecular biologyVirologyVirusHerpes simplex virusBiology
143Publications
41H-index
5,098Citations
What is this?
Publications 144
Newest
#1Emanuele SassoH-Index: 4
Last. Elisa ScarselliH-Index: 20
view all 12 authors...
Oncolytic virotherapy is emerging as a promising therapeutic option for solid tumours. Several oncolytic vectors in clinical testing are based on attenuated viruses; thus, efforts are being taken to develop a new repertoire of oncolytic viruses, based on virulent viral genomes. This possibility, however, raises concerns dealing with the safety features of the virulent phenotypes. We generated a double regulated Herpes simplex type-1 virus (HSV-1), in which tumour cell restricted replicative pote...
Source
#1Laura MenottiH-Index: 17
#2Valerio LeoniH-Index: 8
view all 8 authors...
Source
#1Andrea VanniniH-Index: 7
#2Biljana PetrovicH-Index: 5
Last. Tatiana GianniH-Index: 15
view all 8 authors...
Source
#1Andrea Vannini (UNIBO: University of Bologna)H-Index: 7
#2Valerio Leoni (UNIBO: University of Bologna)H-Index: 8
Last. Tatiana Gianni (UNIBO: University of Bologna)H-Index: 15
view all 8 authors...
Tumors utilize a number of effective strategies, including the programmed death 1/PD ligand 1 (PD-1/PD-L1) axis, to evade immune-mediated control of their growth. PD-L1 expression is mainly induced by IFN receptor signaling or constitutively induced. Integrins are an abundantly expressed class of proteins which play multiple deleterious roles in cancer and exert proangiogenic and prosurvival activities. We asked whether αvβ3-integrin positively regulates PD-L1 expression and the anticancer immun...
2 CitationsSource
#1Francesco Alessandrini (UniGe: University of Genoa)H-Index: 3
#2Laura Menotti (UNIBO: University of Bologna)H-Index: 17
Last. Paolo Malatesta (UniGe: University of Genoa)H-Index: 15
view all 8 authors...
Oncolytic herpes simplex viruses are proving to be effective in clinical trials against a number of cancers. Here, R-115, an oncolytic herpes simplex virus retargeted to human erbB-2, fully virulent in its target cells, and armed with murine interleukin-12 was evaluated in a murine model of glioblastoma. We show that a single R-115 injection in established tumors resulted, in about 30% of animals, in the complete eradication of the tumor, otherwise invariably lethal. The treatment also induced a...
3 CitationsSource
#1Valerio Leoni (UNIBO: University of Bologna)H-Index: 8
#2Andrea Vannini (UNIBO: University of Bologna)H-Index: 7
Last. Gabriella Campadelli-Fiume (UNIBO: University of Bologna)H-Index: 41
view all 11 authors...
Oncolytic herpes simplex viruses (oHSVs) showed efficacy in clinical trials and practice. Most of them gain cancer-specificity from deletions/mutations in genes that counteract the host response, and grow selectively in cancer cells defective in anti-viral response. Because of the deletions/mutations, they are frequently attenuated or over-attenuated. We developed next-generation oHSVs, which carry no deletion/mutation, gain cancer-specificity from specific retargeting to tumor cell receptors—e....
10 CitationsSource
#1Laura Menotti (UNIBO: University of Bologna)H-Index: 17
#2Elisa Avitabile (UNIBO: University of Bologna)H-Index: 21
Last. Gabriella Campadelli-Fiume (UNIBO: University of Bologna)H-Index: 41
view all 6 authors...
Previously, we engineered oncolytic herpes simplex viruses (o-HSVs) retargeted to the HER2 (epidermal growth factor receptor 2) tumor cell specific receptor by the insertion of a single chain antibody (scFv) to HER2 in gD, gH, or gB. Here, the insertion of scFvs to three additional cancer targets—EGFR (epidermal growth factor receptor), EGFRvIII, and PSMA (prostate specific membrane antigen)—in gD Δ6–38 enabled the generation of specifically retargeted o-HSVs. Viable recombinants resulted from t...
5 CitationsSource
Source
#1Valerio LeoniH-Index: 8
#2Biljana PetrovicH-Index: 5
view all 5 authors...
3 CitationsSource
#1Biljana PetrovicH-Index: 5
#2Valerio LeoniH-Index: 8
view all 6 authors...
4 CitationsSource
12345678910